Summary
- Current Price
- As of today, RNA price is $12.11, up +3.15% on
- Current Price All-Time High
- RNA price is currently -27.79% below its historical high of $16.77 set on
- Market Cap
- RNA current market cap is $207M
- Revenue
- RNA current annual revenue is $18.62M, up +70.85% year-over-year
- Next Earnings
- As of today, the next earnings release for RNA has not been scheduled
Profile
| Metric | Value |
|---|---|
| Full Name | Atrium Therapeutics, Inc. |
| Ticker | NASDAQ: RNA |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | atriumtherapeutics.com |
| Employees | 511 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $12.11 | |
| Price, 1D Change | +3.15% | |
| Market Cap | $207M | |
| - | ||
| PE Ratio | - | |
| Beta | 0.86 | |
| Revenue | $18.62M | |
| Revenue, 1Y Change | +70.85% | |
| EPS | -$2.89 | |
| EPS, 1Y Change | -97.04% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | N/A | |
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | -$2.89 | |
| EPS Estimate | -$3.59 | N/A |
| EPS Est. Change | -24.12% | N/A |
| Revenue | $18.62M | |
| Revenue Estimate | $21.60M | N/A |
| Revenue Est. Change | +16.02% | N/A |
| Current Price | $12.11 | |
| Price Target | $25.00 | - |
| Price Tgt. Change | +106.44% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.86 | -$1.47 | +48.63% | |
| -$4.49 | -$2.89 | +35.64% | |
| -$3.59 | N/A | -24.12% | |
| -$5.85 | N/A | -102.25% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $9.75M | $10.90M | +11.76% | |
| $18.36M | $18.62M | +1.41% | |
| $21.60M | N/A | +16.02% | |
| $2.67M | N/A | -85.68% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | - | |
| Price, 3Y | - | |
| Market Cap, 1Y | - | |
| Market Cap, 3Y | - | |
| Revenue, 1Y | +70.85% | |
| Revenue, 3Y | +101.84% | |
| EPS, 1Y | -97.04% | |
| EPS, 3Y | +13.29% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $12.11 | |
| SMA 200 | $13.06 | |
| SMA 50 | $12.38 | |
| EMA 200 | - | |
| EMA 50 | $12.35 | |
| -$0.27 | ||
| Beta | 0.86 | |
| ATR | $0.44 | |
| 14-Day RSI | 51.49 | |
| 10-Day Volatility | 35.06% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $18.62M | |
| EPS | -$2.89 | |
| Gross Profit | $14.60M | |
| Gross Margin | 77.87% | |
| Operating Income | -$745.94M | |
| Operating Margin | -3,977.30% | |
| Net Income | -$49.50M | |
| Net Margin | -3,650.39% | |
| EBITDA | -$741.79M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 0.03 | |
| 9.20 | ||
| 9.20 | ||
| - | ||
| 5 | ||
| -303.15 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | - | |
| 10.11 | ||
| 0.88 | ||
| 1.26 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $1.69B | |
| $1.70B | ||
| $8.95M | ||
| $1.80B | ||
| $71.66M | ||
| $195.45M | ||
| Total Debt | $49.25M | |
| $3.94M | ||
| $12.40M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $703.39M | ||
| $760.55M | ||
| $4.15M | ||
| $0.00 | ||
| $4.15M | ||
| $0.00 | ||
| $0.00 |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| -$650.44M | ||
| -$38.04M | ||
| $850.99M | ||
| Capex | $13.32M | |
| -$663.76M |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Cantor Fitzgerald | ||
| Leerink Partners | ||
| Wells Fargo | ||
| Chardan Capital | → | |
| TD Cowen | → | |
| RBC Capital | → | |
| Chardan Capital | → | |
| Raymond James | → | |
| Needham | → | |
| Leerink Partners | → |
Analyst sentiment
Institutional ownership
No data
Screeners with RNA
FAQ
- What is the ticker symbol for Atrium Therapeutics, Inc.?
- The ticker symbol for Atrium Therapeutics, Inc. is NASDAQ:RNA
- Does Atrium Therapeutics, Inc. pay dividends?
- No, Atrium Therapeutics, Inc. does not pay dividends
- What sector is Atrium Therapeutics, Inc. in?
- Atrium Therapeutics, Inc. is in the Healthcare sector
- What industry is Atrium Therapeutics, Inc. in?
- Atrium Therapeutics, Inc. is in the Biotechnology industry
- What country is Atrium Therapeutics, Inc. based in?
- Atrium Therapeutics, Inc. is headquartered in United States
- When did Atrium Therapeutics, Inc. go public?
- Atrium Therapeutics, Inc. initial public offering (IPO) was on February 27, 2026
- Is Atrium Therapeutics, Inc. in the S&P 500?
- No, Atrium Therapeutics, Inc. is not included in the S&P 500 index
- Is Atrium Therapeutics, Inc. in the NASDAQ 100?
- No, Atrium Therapeutics, Inc. is not included in the NASDAQ 100 index
- Is Atrium Therapeutics, Inc. in the Dow Jones?
- No, Atrium Therapeutics, Inc. is not included in the Dow Jones index
- When was Atrium Therapeutics, Inc. last earnings report?
- Atrium Therapeutics, Inc.'s most recent earnings report was on May 11, 2026
- When does Atrium Therapeutics, Inc. report earnings?
- The date for Atrium Therapeutics, Inc.'s next earnings report has not been announced yet
Data Sources & References
- RNA Official Website www.atriumtherapeutics.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1599901/000159990126000031/0001599901-26-000031-index.htm
- RNA Profile on Yahoo Finance finance.yahoo.com/quote/RNA
- RNA Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/rna